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Introduction: Diabetes mellitus (DM) and intermittent claudication (IC) are frequently associated health conditions.
Our hypothesis is that the nature, severity and quality of life (QoL) of patients with IC and DM are worse than those
of claudicant patients without diabetes.
Material and methods: An observational, cross-sectional and multicentre study of 920 patients with IC, divided
into two groups: diabetic (n = 477) and non-diabetic (n = 443). For each group, we examined clinical and biological
characteristics (including levels of glucose and lipids), the ankle-brachial index (ABI), responses to the Walking
Impairment Questionnaire (WIQ) and the European Quality of Life-5 Dimensions (EQ-5D) questionnaire.
Results: Compared with claudicant patients without diabetes, claudicants with diabetes were older (p < 0.001),
more likely to be female (p = 0.006), with a higher BMI (p < 0.001), more likely to have a sedentary lifestyle
(p < 0.001) and to be a non-smoker (p < 0.001). Claudicant patients with diabetes also had significantly more
cardiovascular risk factors (p < 0.001), more frequent ischaemic cardiopathy (p = 0.023) and chronic renal failure
(p = 0.002), and fewer prior ictus events (p = 0.003). No significant differences between groups were found with
respect to blood pressure, levels of cholesterol or triglycerides. The mean ABI of diabetic-IC patients was slightly
lower than IC patients without diabetes (p = 0.016). All WIQ subdomains scores were significantly lower (p < 0.001),
indicating poorer walking ability, in claudicant and diabetic patients with compared with those without diabetes.
The mean E5-QD global scores and the mean EQ-5D visual analogue scale in the whole series were 0.58 (SD = 0.21)
and 55.04 (SD = 21.30), respectively. Both E5-QD scores were significantly lower, indicating poorer QoL, in claudicant
patients with diabetes than claudicant patients without diabetes (p < 0.001).
Conclusion: Patients with IC and DM had more risk cardiovascular factors, cardiovascular conditions, disability and
worse haemodynamic status and QoL than claudicant patients without diabetes.
Keywords: Diabetes mellitus, Intermittent claudication, Ankle-Brachial index, Walking impairment questionnaire,
Quality of life, EuroQolIntroduction
Peripheral arterial disease (PAD) of the legs has a range
of different clinical presentations, from pain with walk-
ing (intermittent claudication; IC) to gangrene. IC is
always accompanied by different levels of incapacity and
morbidity-mortality (cardiovascular disease-associated)
that significantly impair patients’ quality of life (QoL) [1].* Correspondence: lozano@usal.es
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reproduction in any medium, provided the orThe prevalence of IC is particularly high and variable, as
illustrated by the studies reviewed herein. In the TASC-I
study the prevalence of IC ranged from 0.4% to 14.4% [2].
A cross-sectional study of 1324 participants aged 55 to
84 years conducted in Spain found a prevalence of IC of
8.03% [3].
Diabetes mellitus (DM) is considered the “epidemic of
the 21st century”. The prevalence of DM for all age groups
worldwide was estimated to be 2.8% (171 million) in 2000,
a figure that was predicted to double over the subsequent
two decades [4]. DM is a well-established risk factor for
arteriosclerosis obliterans and diabetic patients often haveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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been a steady rise in the prevalence of diabetes among
claudicant patients, from 2% during 1950 – 1969 to 25%
during 1990 – 1999 [6].
Despite these dramatic figures, there is surprisingly lit-
tle information about diabetic claudicants, especially if
we compare this with other phases (critical limb ischae-
mia) or the process of PAD (diabetic foot) (Table 1). In
the line of Dolan et al. [7] it is important to recognize
the presence of IC in DM patients to prevent most ad-
vances stages of the PAD, frequently lead to the loss of
the limb. This prompted us to test the hypothesis that
the nature, severity and QoL of patients with IC and
DM are worse than those of claudicant patients without
diabetes.Material and methods
An observational, prospective, cross-sectional and multi-
centre study (covering the entire country) was under-
taken between May and December 2011. The study was
approved by the Scientific and Ethics Committee of the
Clinical Hospital, Barcelona, Spain. The study was carried
out by vascular surgeons, members of the Spanish Society
for Angiology and Vascular Surgery. Each participating
investigator included 3–5 consecutive patients with IC
(with or without associated DM).Study population
1,192 patients with IC at least one year before the start
of study were recruited from the entire Spanish territory
by 356 vascular surgeons (VS). VS participants were
invited, via a letter, by an ad hoc committee. All VS
participants are active members of the Spanish Society
of Vascular Angiology and Surgery and were selected
according to predefined selection criteria: a) involvement
in our Society, and b) even geographical distribution.
None of the VS invited refused to participate in the study.Table 1 Distribution of bibliographic references
indicating the fewer studies on intermittent claudication
in diabetes mellitus patients, derived from a literature





Diabetes Mellitus (DM) 322,586 76,595 (23.7%)
Peripheral Arterial Disease (PAD) 59,401 8,167 (13.7%)
Intermittent Claudication (IC) 7,999 1,147 (14.3%)
PAD & DM 3,777 1,067 (28.3%)
IC & DM 667 103 (15.4%)
Diabetic Foot (DF) 8,794 2,597 (29.5%)
Note: The IC & DM group contains 0.2% of the articles about diabetes, 1.7% of
those about PAD and 8.3% of those about IC. There is one article about IC &
DM for every 10 articles about DF.The IC diagnosis was ensured by medical history (in-
cluding Edinburgh questionnaire), physical exploration
and Ankle-brachial Index [3]. All included patients gave
their informed consent to enter the study. Criteria for in-
clusion from the study were: a) lower limb intermittent
claudication (Fontaine grade II), lasting at least 1 year;
b) man or woman; c) aged between 45-85 years; e) any
race. Criteria for exclusion from the study were: a) patient
did not give informed consent to take part in the study;
b) patient with recent admission or with a terminal illness;
c) presence of systemic diseases that could cause an
overall total reduction in mobility (e.g., congestive heart
disease with oxygen therapy, rheumatic diseases and
wheelchair, etc.); d) patient had undergone surgery within
the past 6 months due to limb peripheral artery disease; e)
patient had a major psychiatric condition; f ) alcohol or
drug addiction; g) critical arterial ischaemic limb; h) pa-
tient unable to answer the questions in the WIQ and/or
EQ-5D questionnaires; i) patient unable to understand the
instructions of the study. Patients had to meet all inclusion
criteria in order to be eligible. Some who were otherwise
suitable for inclusion were withdrawn from the study be-
cause they had incomplete clinical questionnaires (< 80%
of items), their ankle-brachial index had not been re-
corded, or the WIQ or EQ-5D questionnaire had not been
fully completed.Measurement instruments
For each patient, the investigator completed a Clinical
Questionnaire (CQ) covering three areas: 1) demographics
and clinical data; 2) blood pressure and laboratory tests
(glycaemia and lipids levels); and 3) ankle-brachial index
(ABI). Additionally, each patient included in the study
filled in two questionnaires: the Walking Impairment
Questionnaire (WIQ) and the European Quality of Life-5
Dimensions (EQ-5D) questionnaire.Ankle-brachial Index (ABI)
A portable Doppler apparatus was used (8 MHz probe).
Techniques were applied according to the recommenda-
tions of the American Heart Association [8]: patient su-
pine and at rest. For each patient, systolic blood pressures
were measured in the following order: dorsalis pedis and
posterior tibial arteries of each leg and both brachials. The
ABI of each extremity was calculated by dividing the high-
est pressure obtained in either of the leg arteries by the
maximum brachial value. In the records of each patient
only the claudicant limb, or the lower ABI in the bilateral
cases, was taken into account. An ABI between 0.90 and
1.2 was considered normal (no patients included). Values
less than 0.90 were consistent with PAD. An ABI value





n = 272 (22.8%)
Patients evaluated 
n = 920 (77.2%)
- Uncompleted  
questionnaires (261)




n = 477 (51.8%)
Non-diabetic group
n = 443 (48.2%)
Figure 1 Study design. CQ = Clinical Questionnaire; ABI = Ankle-
Brachial Index; WIQ =Walking Impairment Questionnaire;
EQ-5D = European Quality of Life-5 Dimensions; DM = Diabetes
Mellitus.
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found in diabetic patients.
Walking Impairment Questionnaire (WIQ)
WIQ is a brief, easy-to-complete, disease-specific ques-
tionnaire specifically designed for assessing the conse-
quences of IC [9]. WIQ has been validated against
treadmill walking test and provides a subjective patient
report of functional walking ability. WIQ is not a QoL
questionnaire but may be used alone or in conjunction
with QoL questionnaires and/or a treadmill exercise
test. The questionnaire addresses aspects related to
walking distance, walking speed, and stair-climbing cap-
acity during the previous month. For walking distance,
the questionnaire considers the degree of difficulty in
walking specified distances. The degree of difficulty for
the corresponding task is expressed on an ordinal scale
from 0 (complete difficulty) to 4 (full capacity to per-
form the task). Each domain is represented as a score
[(Individual Score/4) × 100] ranging from 0% (complete
incapacity) to 100% (full capacity). The questionnaire
typically takes around 5 minutes to complete and has
been validated for interviewer administration or self-
administration. We used the validated Spanish version [10].
European Quality of Life-5 Dimensions (EQ-5D)
questionnaire
EQ-5D was designed by a European group [11]. It is a
QoL general questionnaire widely employed in research
because of its ease of use. It consists of three parts. The
first captures health-related quality of life across five do-
mains: mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression. The scores obtained are sum-
marised as an overall index between 0 (worst health sta-
tus) and 1 (best health status). The second part consists
of a 20-cm, vertical, visual analogue scale (VAS), in the
form of a thermometer, with endpoints of worst and
best imaginable health status (scored 0 and 100, re-
spectively). The third part (the EQ-5D Index) measures
a series of societal preference values and was not evalu-
ated in this study. The EQ-5D has been tested and vali-
dated in patients with IC [12]. We used a Spanish
version [13].
Statistical analysis
All data were anonymously documented to ensure con-
fidentiality, and collated in a PASW version 18 (IBM,
New York, USA). Continuous variables were summarised
as the mean and standard deviation (SD); discrete vari-
ables were expressed as percentages. Continuous variables
with a Gaussian distribution were compared using un-
paired t-tests, while those with a non-Gaussian distri-
bution were compared using the Mann–Whitney test.
Discrete variables were compared by the χ2 or Fisher´sexact test. Fisher’s exact test was performed when ex-
pected percentages were less than 5.
Results
Of the 1192 patients with IC included in the study, 272
were removed (148 and 124 in the diabetic and non-
diabetic groups respectively) because their data were
incomplete (mainly due to the failure to total complete
the WIQ or EQ-5D questionnaire). The sample was
divided into two groups: with and without diabetes
mellitus (n = 477, 51.8% and n = 443, 48.2%, respectively)
(Figure 1).
Clinical features of patients by diabetes status
The main clinical features of the patients with IC with
respect to the presence or absence of diabetes are listed
in Table 2. Overall, there was a clear predominance of
men (77.9%), sedentary lifestyles (57.4%) and a family
history of cardiovascular disease (58.8%). The mean age
of the total series was 68.2 (SD = 9.8) years and the mean
BMI was 27.6 (3.6). Compared with claudicant patients
without diabetes, claudicants with diabetes were older
(p < 0.001), more likely to be female (p = 0.006), with a
higher BMI (p < 0.001) and more likely to have a seden-
tary lifestyle (p < 0.001). Claudicant patients with dia-
betes more often had hypertension (p < 0.001) than
those without diabetes. Almost 48.2% of claudicants with
diabetes had at least three risk factors for cardiovascular
disease, compared with only 16.3% of claudicants with-
out diabetes. On the other hand, active smoking was








Male (n, %) 355 (74.4) 362 (81.7) 717 (77.9) 0.006
Year (mean, SD) 69.8 (9.3) 66.4 (10.0) 68.2 (9.8) < 0.001
BMI (mean, SD) 28.2 (3.7) 26.9 (3.4) 27.6 (3.6) < 0.001
Sedentarism (n, %) 317 (66.5) 211 (47.6) 528 (57.4) < 0.001
Ex-smoker (n, %) 178 (37.3) 171 (38.6) 349 (37.9) 0.085
Cardiovascular (CV) risk factor (n, %)
Smoker 168 (35.2) 189 (42.7) 357 (38.8) < 0.001
Diabetic mellitus 477 (100) 0 (0) 477 (100) < 0.001
Hypertension 385 (80.7) 313 (70.7) 698 (75.9) < 0.001
Dyslipidaemia 311 (65.2) 280 (63.2) 591 (64.2) 0.528
Number of CV risk factors
None 0 (0.0) 23 (5.2) 23 (2.5) < 0.001
One 29 (6.1) 130 (29.3) 159 (17.3)
Two 125 (26.2) 218 (49.2) 343 (37.3)
Three 230 (48.2) 72 (16.3) 302 (32.8)
All (four) 93 (19.5) 0 (0.0) 93 (10.1)
CV disease-associated conditions (n, %)
Cardiac failure 50 (10.5) 36 (8.1) 86 (9.3) 0.220
Ischaemic cardiopathy 160 (33.5) 118 (26.6) 278 (30.2) 0.023
Arrythmias 54 (11.3) 31 (7.0) 85 (9.2) 0.024
Valvulopathy 22 (4.6) 11 (2.5) 33 (3.6) 0.083
Chronic renal failure 53 (11.1) 24 (5.4) 77 (8.4) 0.002
Prior CV diseases (n, %)
Myocardial infarction 62 (14.0) 67 (14.0) 129 (14.0) 0.982
Angina pectoris 38 (8.6) 48 (10.1) 86 (9.3) 0.439
Stroke 4 (0.9) 19 (4.0) 23 (2.5) 0.003
Osteoarticular diseases (n, %)
Arthrosis 263 (55.1) 158 (35.7) 421 (45.8) < 0.001
Arthritis 21 (4.4) 21 (4.7) 42 (4.6) 0.806
Vertebral disc prolapse 45 (9.4) 36 (8.1) 81 (8.8) 0.484
Lumbar pathology 83 (17.4) 69 (15.6) 152 (16.5) 0.456
Major trauma 5 (1.0) 4 (0.9) 9 (1.0) 1.000
Family history of
CV disease (n, %) 295 (61.8) 246 (55.5) 541 (58.8) 0.095
BMI = Body mass index.
*Diabetic group vs non-diabetic group.
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betic claudicants (p < 0.001).
The most common cardiovascular disease associated
with IC was ischaemic cardiopathy (30.2% of the total
series). Compared with non-diabetic claudicants, those
with diabetes more frequently exhibited ischaemic cardi-
opathy (33.5% vs. 26.6%, p = 0.023) and chronic renalfailure (11.1% vs. 5.4%, p = 0.002). Other cardiovascular
diseases (congestive cardiac failure, arrhythmias or valvu-
lopathies) were similarly less frequent in both groups.
There were histories of myocardial infarction or angina
pectoris of 14.0% and 9.3%, respectively, in the whole
series. No significant differences between claudicant
patients with or without diabetes were found with
Lozano et al. Diabetology & Metabolic Syndrome 2014, 6:21 Page 5 of 8
http://www.dmsjournal.com/content/6/1/21regard to the history of myocardial infarction or angina
pectoris, but a history of stroke was more frequent in
claudicant patients without diabetes than in those with
diabetes (p = 0.003).
The most common osteoarticular comorbid conditions
were arthrosis (45.8%) and lumbar pathology (16.5%).
Arthrosis was significantly more frequent in IC with
than without diabetes (55.1% vs. 35.7%, p < 0.001). Lumbar
pathology and other osteoarticular comorbidities (arthritis,
vertebral disc prolapse and major trauma) occurred at
similarly lower frequencies in the two groups.
No significant differences between the groups were
found with regard to blood pressure, levels of cholesterol
and triglycerides. The mean ABI of the total series was
0.63 (SD = 0.19). The ABI was significantly lower in clau-




SBP (mm Hg) 144.0 (17.8)










> 1.30 29 (6.1)
0.90-0.50 343 (71.9)
< 0.50 105 (22.0)
WIQ
Pain (mean%) 44.29 (20.05)
Walking distance 1395.60 (1136.22) 18
Distance (mean%) 29.79 (24.26)
Walking speed 14.54 (9.65)
Speed (mean%) 31.62 (20.99)
Stair-climbing 106.11 (76.48) 1
Stair-climbing (mean%) 36.84 (26.56)
EQ-5D†
Global score 0.54 (0.22)
VAS score (mean%) 53.31 (20.54)
†0-1 or 0-100% (worst – best quality of life).
SBP = Systolic blood pressure.
DBP = Diastolic blood pressure.
HDL = High-density lipoprotein: LDL = Low-density lipoprotein.
ABI = Ankle-brachial index; WIQ =Walking Impairment Questionnaire; EQ-5D = EuroQ
*Diabetic group vs non-diabetic group.
Values are the mean (and standard deviation), except where indicated as being freqp = 0.016). An ABI less than 0.50 was detected in 170
claudicant patients, such values being more frequent
amongst those with diabetes than those without (22.0%
vs. 14.7%, p = 0.033).
WIQ and EQ-5D of patients by diabetes status
WIQ and EQ-5D scores are shown in Table 3. The mean
walking distance, walking speed and stair-climbing cap-
acity in the entire series were 34.07 (SD = 26.77), 35.43
(SD = 23.0) and 41.16 (SD = 28.54), respectively. All WIQ
subdomains scores were significantly lower, indicating
poorer walking capability, in claudicant patients with
diabetes than in claudicant patients without diabetes
(p < 0.001 for all comparisons). Pain was more severe
in claudicants with diabetes than in those without






142.8 (17.5) 143.4 (17.7) 0.540
81.5 (10.6) 81.5 (10.6) 0.647
101.2 (21.6) 130.1 (45.1) < 0.001
209.8 (44.8) 208.4 (47.1) 0.244
52.1 (26.6) 51.9 (27.8) 0.078
130.8 (39.1) 128.2 (39.7) 0.118
155.7 (79.7) 158.9 (77.4) 0.102
0.64 (0.15) 0.63 (0.19) 0.016
26 (5.9) 55 (6.0) 0.033
352 (79.4) 695 (75.5)
65 (14.7) 170 (18.5)
50.17 (20.35) 47.12 (20.40) < 0.001
11.26 (1337.63) 1595.75 (1253.96) < 0.001
38.67 (28.56) 34.07 (26.77) < 0.001
18.19 (11.21) 16.30 (10.59) < 0.001
39.54 (24.38) 35.43 (23.00) < 0.001
31.92 (86.01) 118.54 (82.19) < 0.001
45.81 (29.86) 41.16 (28.54) < 0.001
0.62 (0.19) 0.58 (0.21) < 0.001
56.92 (21.97) 55.04 (21.30) 0.003
ol.
uency and percentage.
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visual analogue scale in the overall series were 0.58
(SD = 0.21) and 55.04 (SD = 21.30), respectively. Both
E5-QD scores were significantly lower, indicating poorer
QoL, in claudicant patients with diabetes than in those
without diabetes (p < 0.001).
Discussion
Our results indicate that claudicant patients with diabetes
have some distinct clinical characteristics as well as more
severe disease and poorer QoL than claudicant patients
without diabetes.
The medical-social and economic consequences of
PAD and IC are very important, as is apparent from the
extensive bibliography. PAD is a major public health
problem in western countries. IC is a common, chronic
disease that can cause injuries throughout a substantial
portion of a patient’s life. The true prevalence of PAD in
people with diabetes has been difficult to determine be-
cause most patients are asymptomatic. Population-based
studies have revealed a prevalence of PAD in people with
diabetes of up to 30% [14]. PAD is equally prevalent in
type 1 and type 2 diabetes, although some authors report
a higher prevalence in type 2 diabetes, which is the more
common diabetes [5]. According to the HUNT study,
the prevalence of IC in patients with DM was more than
three times that in non-diabetic participants [15]. How-
ever, it is significant and notable that the prevalence of





















































































Figure 2 QoL measured by EQ-5D in several chronic diseases. DM= D
Pulmonary Disease (Rutten-van Mölken et al. 2006); CHF = Chronic Heart Failulower than that of critical limb ischaemia (CLI) in this
population [16]. The characteristics of the macro- and
micro-angiopathy in the diabetic population lead to an
IC that is less benign than that in the non-diabetic
population, and the PAD in diabetic patients would be
much more pronounced and the progression of the
disease more rapid. Therefore, it is important to detect
and measure the characteristics of IC in the diabetic
population.
The characteristics of our series are quite similar to
those of other series examined throughout the world
[6,17]. Diabetic claudicants have a substantial burden of
cardiovascular risk factors, prior cardiovascular disease
or cardiovascular disease-associated conditions. However,
we have not found any satisfactory explanation for the
lower prevalence of smoking and history of stroke among
diabetic PAD/IC patients. The association of osteoarticular
disease in claudicant patients is a phenomenon that has
been little studied. Breek et al. [18] showed that the back,
hip and knee symptoms were very prevalent in IC. In our
series, up to half of the claudicant patients had arthrosis,
and their walking capability and QoL could be partially
predicted by the presence of osteoarticular comoborbidity.
As other authors have observed [19,20], we found statis-
tically significant differences in the level of lipids between
diabetic and non-diabetic claudicants.
The mean ABI in our total series was 0.63 (SD = 0.19).
Similar mean ABIs have been found in previous studies

































iabetes Mellitus (Janssen et al. 2001); COPD = Chronic Obstructive
re (de Rivas et al. 2008); IC = Intermittent Claudication (present study).
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than that for PAD without diabetes [7,20,25], this differ-
ence being statistically significant in our study.
However, the most outstanding feature of ABI in the
diabetic population is its diagnostic and prognostic value
[25]. ABI thresholds of less than 0.9 and more than 1.3
are highly suggestive of PAD in diabetic patients [26]
while, conversely, diabetics with an ABI > 1.40 have a
poorer prognosis [27].
Walking deterioration measured by the WIQ in our
series was reasonably consistent with the results of pre-
vious studies [7,9,22,28]. The mean estimate of pain was
47.1 (range in previous studies = 39.6 – 63.3), walking
distance was 34.1 (range in previous studies = 22.6 – 55.0),
walking speed was 35.4 (range in previous studies =
23.9 – 48.3) and stair-climbing capacity was 41.2 (range in
previous studies = 23.8 – 65.0). We should emphasise that
walking deterioration was significantly poorer in claudicant
patients with diabetes than in those without, as other
authors have reported [7,19,20].
It is well know that PAD is associated with a significant
reduction in quality of life. Specifically, IC represents a de-
terioration in QoL compared with controls [29]. Accord-
ingly, the mean QoL measured by EQ-5D in our series
(0.58, SD = 0.21) is similar to the values from studies
from various parts of the world. Again, claudicant pa-
tients with diabetes had poorer QoL than their coun-
terparts without diabetes [19,30-33], irrespective of the
type of diabetes [18,30-32].
Atherosclerotic disease, specifically angina pectoris,
causes a greater deterioration of QoL in IC [29]. As our
study indicates, the presence of atherosclerotic disease is
more frequent in diabetes. Osteoarticular disease can
also affect walking [18]. It is possible that this comorbidity
might partly explain the worse QoL of diabetic patients,
but it has been little studied. Other factors contribute to
the deterioration of QoL in diabetic patients. First, PAD
patients with more metabolic syndrome components have
a worse quality of life [34]. Second, a recent longitudinal
study has shown that the QoL of diabetic patients declined
over 5 years, due, among other reasons, to the develop-
ment of complications [35]. Thus, the development of ne-
phropathy [30], retinopathy and neuropathy are predictors
of lower QoL [31].
Two systematic reviews of QoL and IC revealed that
deterioration in QoL affected the physical domain more
than the psychological and social domains [36,37]. Lower
ABI values are associated with significantly lower physical
activity [22,38]. In fact, for some authors, the objective ap-
proach most closely correlated with QoL is the walking
capability by treadmill test [21,22] or WIQ [22,38]. In
contrast, QoL in diabetic claudicants was worse than in
non-diabetic claudicants but was comparable to patients
with severe chronic disease [31,39-41] (Figure 2).Our study had several characteristics that differentiate
it from other studies with similar aims: a) the large num-
ber of patients (n = 920 claudicants), which increases the
reliability of our results; b) our study covered the whole
country, thereby encompassing cultural variability; and
c) the scoring of several parameters. Finally, the biggest
potential limitation of our study was the lack of the tread-
mill test. However, PAD and WIQ are well correlated.
In conclusion, patients with IC and diabetes had more
risk cardiovascular factors, cardiovascular conditions, dis-
ability and a poorer haemodynamic status and QoL than
claudicant patients without diabetes.
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